We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

02 Jun 2025 - 04 Jun 2025
11 Jun 2025 - 13 Jun 2025

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

By LabMedica International staff writers
Posted on 16 Jul 2024

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes have occurred. More...

Historically, a definitive diagnosis of Alzheimer’s disease could only be confirmed through an autopsy. In the last two decades, advanced brain imaging techniques such as PET, CT, and MRI have been developed to aid in the diagnosis of Alzheimer’s disease more reliably; however, these methods are costly, expose patients to radiation, and are not accessible to everyone. In search of a more accessible and straightforward method to assess brain health, the focus has shifted towards biomarkers. The detection of biomarkers in blood is now seen as the future of Alzheimer’s disease diagnosis. Now, a new collaboration for the use of a proprietary antibody to detect a crucial biomarker for Alzheimer's through a blood test marks a significant step forward in diagnosing the disease.

Beckman Coulter Diagnostics (Brea, CA, USA) has signed a licensing agreement with ALZpath Inc. (Carlsbad, CA, USA) to use its top-tier ALZpath pTau217 antibody in a blood-based in vitro diagnostic (IVD) test on its DxI 9000 Immunoassay Analyzer. This proprietary ALZpath pTau217 antibody, employed in blood-based assays, has demonstrated high diagnostic accuracy, sensitivity, and reliability in identifying the presence and progression of Alzheimer's disease—information that is increasingly vital for clinicians and researchers as new treatment options become available.

Blood-based assays using the ALZpath pTau217 antibody offer diagnostic accuracy comparable to traditional methods like PET imaging and cerebral spinal fluid (CSF) testing, but they are more accessible and affordable, involving a simple, less invasive blood test that can be performed in various clinical settings. The DxI 9000 Immunoassay Analyzer, available worldwide, is Beckman Coulter's latest immunoassay platform. It features the unique Lumi-Phos PRO substrate, facilitating the development of clinically relevant, highly sensitive assays that meet the evolving demands of healthcare. The DxI 9000 combines this enhanced sensitivity with leading throughput, reliability, reproducibility, and quality in core laboratory operations, along with a comprehensive menu of tests.

"We recognize the critical need for more sensitive, precise, and scalable diagnostic testing for Alzheimer's disease," said Kathleen Orland, senior vice president, general manager, Chemistry, and Immunoassay for Beckman Coulter Diagnostics. "We selected ALZpath's pTau217 antibody following rigorous evaluation due to its high performance in detecting amyloid pathology and ability to integrate into our advanced DxI 9000 platform to support broad-based testing. We are excited about the combination of ALZpath and Beckman Coulter innovations coming together to develop a new fully automated, high throughput, blood-based Alzheimer's disease test for the millions of patients who suffer from dementia worldwide."

"Alzheimer's disease affects tens of millions of people worldwide, but many remain undiagnosed and are consequently unable to be identified for clinical trials or get access to emerging treatments," added Chad Holland, CEO and president at ALZpath. "Collaborating with Beckman Coulter to integrate our pTau217 antibody into a highly accurate blood-based test run on their DxI 9000 analyzers will significantly expand access to precise testing and early diagnosis for patients around the world."

Related Links:
Beckman Coulter Diagnostics 
ALZpath Inc.


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Enterovirus Test
Quanty Enterovirus System
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New biomarkers could someday make it easy to spot Parkinson’s disease in a patient’s blood sample (Photo courtesy of Shutterstock)

Unique Blood-Based Genetic Signature Can Diagnose Parkinson’s Disease

Parkinson's disease is primarily recognized for its impact on the central nervous system. Recent scientific progress has shifted focus to understanding the involvement of the immune system in the onset... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The new tool is designed for accurate detection of structural variations in clinical samples (Photo courtesy of Karen Arnott/EMBL-EBI and Isabel Romero Calvo/EMBL)

ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data

Long-read sequencing technologies are designed to analyze long, continuous stretches of DNA, offering significant potential to enhance researchers' abilities to detect complex genetic changes in cancer genomes.... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.